Page 7 - Genevant Sciences News Today

IAM looks back at the most important pharmaceuticals developments of the past 12 months

The global Lipid Nanoparticles Market size is expected to be valued at US$ 887.2 Million in 2023. With the increasing health concern among people for dietary supplements, in the light of Covid-19, coupled with the growing dietary supplement consumption, the overall demand for Lipid Nanoparticles is projected to grow...

BioPharma

Recent lawsuits on mRNA technology are attempts by various corporations to take control of these vital discoveries for their own enrichment. Recent advances in molecular technology that allows for gene editing and protein manufacturing portend a revolution in medicine that can offer personalized treatments for a broad array of diseases.

Arbutus Biopharma stock seems to be building a floor at current trading levels. Read more for a full investment analysis of ABUS stock.

Moderna's patent-infringement suit was a ‘de facto recognition’ of the end of the pandemic, one pundit said. What happens now?

Biotechnology major Moderna on Friday sued rival Pfizer and BioNTech over alleged infringement of its messenger RNA (mRNA) vaccine technology patents.

Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities

Moderna yesterday filed patent infringement lawsuits against Pfizer and BioNTech, alleging the two companies copied Moderna’s patented mRNA ...

Moderna sued Pfizer and BioNTech on Aug. 26, alleging the companies infringed on its patents for technology utilized ...